Objective: To measure urine malondialdehyde (MDA) and urine peroxynitrite (ONOO) levels in patients with overactive bladder (OAB), and compare them with healthy individuals; to determine the change of those markers in OAB patients prescribed antimuscarinic drugs. Study Design: An observational study. Place and Duration of Study: The Department of Urology, School of Medicine, University of Gaziantep, Gaziantep, Turkey, between August 2021 and February 2022. Methodology: Patients diagnosed with OAB (Group 1), and healthy controls (Group 2) were compared. Urinary MDA (µmol/L) and ONOO (µmol/L) levels were measured in all participants. The patients diagnosed with OAB were underwent antimuscarinic therapy with propiverine 30 mg. The levels of MDA (µmol/L) and ONOO (µmol/L) were reanalysed during the third month of antimuscarinic therapy. Patients with stress urinary incontinence, neurogenic bladder, pelvic organ prolapse stage e3 (POP Q e3), interstitial cystitis (bladder pain syndrome), history of pelvic radiotherapy, symptoms of bladder outlet obstruction, Qmax 0.05). Although no signi cant change was detected in MDA levels after antimuscarinic therapy (3.50 ± 1.19 µmol/L, p=0.529), there was a statistically signi cant increase in ONOO levels (1.49 ± 1.45 µmol/L, p=0.013). Conclusion: MDA might be used in the diagnosis of OAB, as a biomarker, similar to recent studies. ONOO was evaluated for the rst time in the literature for the diagnosis of OAB, unfortunately, no signi cant outcomes were obtained. In addition, both MDA and ONOO had no role in monitoring antimuscarinic therapy.